Medical cannabis company Odi Pharma reports increased revenue in the fourth quarter compared with the same period a year earlier. The operating result turned to a profit.Revenue amounted to SEK 3.2 million, compared with a modest approximately SEK 6,500 last year. At the same time, the company had revenue of SEK 12.8 million in the previous quarter."The sequential decline was mainly due to the timing of orders, as our largest customer placed a larger order toward the end of the third quarter and therefore only needed a smaller order during the fourth quarter. Against the backdrop of the strong performance for the full year, we do not view the lower sales level in the fourth quarter as a sign of weaker underlying demand," comments Chairman Volker Wiederrich.Operating profit was SEK 0.15 million (-1.5), with an operating margin of 4.7 percent. Profit after tax was SEK 0.15 million (-1.7). Cash flow from operating activities amounted to SEK 0.1 million (-1.5). Cash and cash equivalents amounted to SEK 3.4 million (1.5).No dividend is proposed.According to Wiederrich, Odi Pharma is entering the new fiscal year with a larger commercial base, improved profitability and a strengthened balance sheet. The company's top priority is to consolidate and strengthen its position in Poland.At the same time, Odi Pharma is monitoring developments in the European medical cannabis market, including in France, to evaluate future opportunities.Odi Pharma, SEK millionQ4-2025/2026Q4-2024/2025ChangeNet sales3.20.0Operating result0.15-1.5Operating margin4.7%Net result0.15-1.7Cash flow from operating activities0.1-1.5Cash and cash equivalents3.41.5126.7%